1.Risk Factor Analysis for C5 Palsy after Double-Door Laminoplasty for Cervical Spondylotic Myelopathy.
Satoshi BABA ; Ko IKUTA ; Hiroko IKEUCHI ; Makoto SHIRAKI ; Norihiro KOMIYA ; Takahiro KITAMURA ; Hideyuki SENBA ; Satoshi SHIDAHARA
Asian Spine Journal 2016;10(2):298-308
STUDY DESIGN: A retrospective comparative study. PURPOSE: To clarify the risk factors related to the development of postoperative C5 palsy through radiological studies after cervical double-door laminoplasty (DDL). OVERVIEW OF LITERATURE: Although postoperative C5 palsy is generally considered to be the result of damage to the nerve root or segmental spinal cord, the associated pathology remains controversial. METHODS: A consecutive case series of 47 patients with cervical spondylotic myelopathy treated by DDL at our institution between April 2008 and April 2015 were reviewed. Postoperative C5 palsy occurred in 5 of 47 cases after DDL. We investigated 9 radiologic factors that have been reported to be risk factors for C5 palsy in various studies, and statistically examined these between the two groups of palsy and the non-palsy patients. RESULTS: We found a significant difference between patients with and without postoperative C5 palsy with regards to the posterior shift of spinal cord at C4/5 (p=0.008). The logistic regression analyses revealed posterior shift of the spinal cord at C4/5 (odds ratio, 12.066; p=0.029; 95% confidence interval, 1.295–112.378). For the other radiologic factors, there were no statistically significant differences between the two groups. CONCLUSIONS: In the present study, we showed a significant difference in the posterior shift of the spinal cord at C4/5 between the palsy and the non-palsy groups, indicating that the "tethering phenomenon" was likely a greater risk factor for postoperative C5 palsy.
Humans
;
Logistic Models
;
Paralysis*
;
Pathology
;
Retrospective Studies
;
Risk Factors*
;
Spinal Cord
;
Spinal Cord Diseases*
2.Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review
Isao MURAKAMI ; Hiroko MACHIDA ; Tohru MORISADA ; Yasuhisa TERAO ; Tsutomu TABATA ; Mikio MIKAMI ; Yasuyuki HIRASHIMA ; Yoichi KOBAYASHI ; Tsukasa BABA ; Satoru NAGASE
Journal of Gynecologic Oncology 2023;34(4):e49-
Objective:
To examine the effectiveness of progestin re-treatment for recurrent endometrial intraepithelial neoplasia (EIN), atypical endometrial hyperplasia (AH) and endometrial cancer (EC) following initial fertility-sparing treatment.
Methods:
A comprehensive systematic review and meta-analysis were conducted by an Expert Panel of the Japan Society of Gynecologic Oncology Endometrial Cancer Committee. Multiple search engines, including PubMed/MEDLINE and the Cochrane Database, were searched in December 2021 using the keywords “Endometrial neoplasms,” “Endometrial hyperplasia,” “Endometrial intraepithelial neoplasia,” “Fertility preservation,” “Progestins,” AND “Recurrence.” Cases describing progestin re-treatment for recurrent EIN, AH and EC were compared with cases that underwent conventional hysterectomy. The primary outcomes were survival and disease recurrence, and the secondary outcome was pregnancy.
Results:
After screening 238 studies, 32 with results for recurrent treatment were identified. These studies included 365 patients (270 received progestin re-treatment and 95 underwent hysterectomy). Most progestin re-treatment involved medroxyprogesterone acetate or megestrol acetate (94.5%). Complete remission (CR) following progestin re-treatment was achieved in 219 (81.1%) cases, with 3-, 6- and 9-month cumulative CR rates of 22.8%, 51.7% and 82.6%, respectively. Progestin re-treatment was associated with higher risk of disease recurrence than conventional hysterectomy was (odds ratio [OR]=6.78; 95% confidence interval [CI]=1.99–23.10), and one patient (0.4%) died of disease. Fifty-one (14.0%) women became pregnant after recurrence, and progestin re-treatment demonstrated a possibility of pregnancy (OR=2.48; 95% CI=0.94–6.58).
Conclusion
This meta-analysis suggests that repeat progestin therapy is an effective option for women with recurrent EIN, AH and EC, who wish to retain their fertility.
3.A Survey on Effects of Caffeine in Psychiatric Outpatients
Erika DEGAWA ; Takahito ANDO ; Masazumi ANDO ; Tsuyoshi KATO ; Toshi SHIMAMURA ; Akane NAGATA ; Tetsuo MURANO ; Hiroaki HAYASHI ; Hiroko BABA ; Moemi SAITO
Japanese Journal of Drug Informatics 2018;20(3):189-199
Objective: Caffeine may cause dependence and sleep disturbance, and interact with psychotropic drugs. Therefore, the caffeine intake of patients with mental disorders should be monitored. However, in Japan, there is no report on the effects of caffeine in mental disease patients or on their caffeine intake. Therefore, we conducted a questionnaire survey to clarify the perception of caffeine for psychiatric outpatients.Methods: We conducted an anonymous survey on caffeine recognition for outpatients at 8 medical institutions that advocate psychiatry.Results: We collected questionnaires from 180 people. The knowledge of foods containing caffeine tended to be high in those who had a positive attitude toward caffeine. More than 90% of those surveyed knew that coffee contains caffeine, but cocoa and jasmine tea were recognized by less than 25%. Of those surveyed, 39.4% consumed caffeine‐containing beverages at night. In addition, the rate of consumption of caffeine‐containing beverages tended to be higher at night because they had a positive attitude toward caffeine.Conclusion: The knowledge and intake situation of caffeine by patients with mental disorders differed depending on their interests and way of thinking about caffeine. As caffeine intake may influence psychiatric treatment, correct knowledge regarding caffeine is important.
4.Clinical utility of CA-125 in the management of uterine carcinosarcoma.
Koji MATSUO ; Malcolm S ROSS ; Mayu YUNOKAWA ; Marian S JOHNSON ; Hiroko MACHIDA ; Kohei OMATSU ; Merieme M KLOBOCISTA ; Dwight D IM ; Shinya SATOH ; Tsukasa BABA ; Yuji IKEDA ; Stephen H BUSH ; Kosei HASEGAWA ; Erin A BLAKE ; Munetaka TAKEKUMA ; Masako SHIDA ; Masato NISHIMURA ; Sosuke ADACHI ; Tanja PEJOVIC ; Satoshi TAKEUCHI ; Takuhei YOKOYAMA ; Yutaka UEDA ; Keita IWASAKI ; Takahito M MIYAKE ; Shiori YANAI ; Tadayoshi NAGANO ; Tadao TAKANO ; Mian MK SHAHZAD ; Frederick R UELAND ; Joseph L KELLEY ; Lynda D ROMAN
Journal of Gynecologic Oncology 2018;29(6):e88-
No abstract available.
Carcinosarcoma*